| __timestamp | MiMedx Group, Inc. | Rhythm Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 90480000 | 1213000 |
| Thursday, January 1, 2015 | 133384000 | 3425000 |
| Friday, January 1, 2016 | 179997000 | 6311000 |
| Sunday, January 1, 2017 | 220119000 | 9518000 |
| Monday, January 1, 2018 | 258528000 | 28080000 |
| Tuesday, January 1, 2019 | 198205000 | 36550000 |
| Wednesday, January 1, 2020 | 181022000 | 46125000 |
| Friday, January 1, 2021 | 198359000 | 68486000 |
| Saturday, January 1, 2022 | 208789000 | 92032000 |
| Sunday, January 1, 2023 | 211124000 | 117532000 |
In pursuit of knowledge
In the competitive landscape of pharmaceuticals, effective cost management is crucial. Over the past decade, MiMedx Group, Inc. and Rhythm Pharmaceuticals, Inc. have demonstrated contrasting trajectories in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, MiMedx Group's SG&A expenses surged by approximately 133%, peaking in 2018. This reflects a strategic expansion phase, possibly linked to increased marketing and administrative efforts. In contrast, Rhythm Pharmaceuticals, Inc. exhibited a staggering 9,600% increase in SG&A expenses, highlighting its aggressive growth strategy and market penetration efforts. Notably, Rhythm's expenses reached their zenith in 2023, indicating a robust push towards market leadership. These trends underscore the dynamic nature of cost management in the pharmaceutical sector, where strategic investments in SG&A can significantly influence a company's market position.
Selling, General, and Administrative Costs: Novo Nordisk A/S vs MiMedx Group, Inc.
Cost Management Insights: SG&A Expenses for Sanofi and Rhythm Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Sanofi and MiMedx Group, Inc.
Comparing SG&A Expenses: Zoetis Inc. vs Rhythm Pharmaceuticals, Inc. Trends and Insights
Incyte Corporation and MiMedx Group, Inc.: SG&A Spending Patterns Compared
Jazz Pharmaceuticals plc vs MiMedx Group, Inc.: SG&A Expense Trends
Selling, General, and Administrative Costs: Halozyme Therapeutics, Inc. vs MiMedx Group, Inc.
Comparing SG&A Expenses: Alkermes plc vs MiMedx Group, Inc. Trends and Insights
Comparing SG&A Expenses: Verona Pharma plc vs MiMedx Group, Inc. Trends and Insights
SG&A Efficiency Analysis: Comparing Rhythm Pharmaceuticals, Inc. and Xenon Pharmaceuticals Inc.
Selling, General, and Administrative Costs: Rhythm Pharmaceuticals, Inc. vs Dynavax Technologies Corporation
Breaking Down SG&A Expenses: Rhythm Pharmaceuticals, Inc. vs Taro Pharmaceutical Industries Ltd.